Macro Notes

Macro Notes

Obesity Had Its Drug. Mental Health Is About to Get Its First

Why I’m Still Betting on Mental Health After a 126% Run

Macro Notes's avatar
Pierre MJ's avatar
Macro Notes and Pierre MJ
Nov 16, 2026
∙ Paid

Right now, under US federal law, psilocybin sits in the same legal category as heroin.

By January, a doctor may be able to prescribe it.

I know how that sounds. A few years ago I would have filed “psychedelic medicine” somewhere between cold fusion and the metaverse: a great story, a terrible investment. Then one company ran two large clinical trials, both worked, and on November 9 it handed the FDA a complete application.

That company is Compass Pathways.

In July, Eli Lilly agreed to pay $2.8 billion in cash, and up to $3.8 billion with milestones, for a competitor whose lead product had only just started its final round of trials. The deal closed on September 11.

Compass, which has finished that final round twice, with more than 1,000 patients, is worth about $1.3 billion. That is 141.7 million shares at the $9.01 they closed at on Friday, November 13. And $444 million of it is simply cash in the bank.

The company closest to the finish line is worth less than half of what Lilly paid, in cash, for the one that just left the starting blocks.

When the market prices something that strangely, there are only two possibilities. Either the market knows something. Or the market is measuring the wrong thing.

I think it is measuring the wrong thing. Let me show you why, step by step.

First, what are we actually talking about?

A quick word on the disease.

Most people with depression get better on a standard antidepressant. But a large group does not. They try one drug, then a second, and nothing moves. Doctors call this treatment-resistant depression.

There are roughly 4 million of these patients in the United States. Fewer than 5% of them receive a therapy actually designed for their situation.

Think about that as an investor. Four million people, a serious illness, and a market that is more than 95% unserved. You almost never see that outside of rare diseases.

Compass’s drug is called COMP360. It is a pharmaceutical-grade, synthetic version of psilocybin, the active compound in so-called magic mushrooms. The patient does not take it home. They take it in a clinic, in a quiet room, with a trained professional in attendance for the whole experience.

Does it work?

Short answer: yes, modestly, and unusually fast.

A quick word on how depression is measured. Trials use a questionnaire called MADRS. A doctor scores the patient from 0 to 60, and the higher the score, the worse the depression. A drug “works” if treated patients drop meaningfully further than those who got a placebo.

Here is what the two final-stage trials showed:

TRIAL      WHAT PATIENTS GOT               EXTRA DROP AT WEEK 6     RESPONDERS
COMP005    one 25 mg dose                  3.6 pts vs placebo       25%
COMP006    two doses, 3 weeks apart        3.8 pts vs tiny dose     39%

Let’s be clear: a gap of 3.6 points on a 60-point scale is not a miracle cure.

But look at what surrounds that number. The improvement appeared the day after dosing. Standard antidepressants take weeks. In the patients who responded, the benefit was still there six months later, after one or two doses. And these were people who had been stuck in their current episode for more than three years on average.

Just one or two doses over six months, in patients for whom every other treatment had failed.

That is not a better antidepressant. It is a different kind of product.

So why is the market so unimpressed?

Because of a chair.

To see it, you need to know about a drug called Spravato. It is a nasal spray from Johnson & Johnson, a chemical cousin of ketamine, approved in March 2019 for the same patients.

Spravato started slowly. Then it took off: about $1.7 billion in sales in 2025, and $584 million in the second quarter of 2026 alone.

What changed was not the drug. It was the infrastructure. Around 3,000 certified clinics now offer it, and they all run the same routine: the patient sprays, sits in a chair under observation for about two hours, and goes home.

Two hours matters. A clinic can run several patients through the same chair in a day. The economics work.

Now you can understand why Lilly wrote that check. The product it bought, a nasal spray called BPL-003, is a psychedelic designed to fit that exact routine. Its effects fade in about 90 minutes, and more than 80% of patients are ready to leave within two hours.

Psilocybin does not fit. The experience lasts most of a day. In Compass’s trials, a dosing session ran six to eight hours, with trained therapists in the room. The company expects about six hours of monitoring in real-world use. Compass’s rivals have turned this into a one-line sales pitch: would you rather monitor a patient for two hours, or for eight?

That is the consensus view in one sentence. The short session wins, the long session loses, and Compass is on the wrong side.

It is a reasonable argument. I just think it stops one step too early.

Forty afternoons versus three days

The mistake is to count hours per session. What matters is hours per patient, per year.

Here is the difference. Spravato is not a one-time treatment. The label calls for two sessions a week during the first month, then one every week or two, indefinitely. Compass expects its patients to need two to four sessions a year, three on average.

So I did the arithmetic.

                   SESSIONS / YEAR    HOURS EACH    CHAIR HOURS / YEAR
Spravato           34 to 56           2 minimum     68 to 112
COMP360            2 to 4 (avg 3)     about 6       12 to 24 (avg 18)

The Spravato schedule and its two-hour minimum come straight from the drug’s prescribing information: eight sessions in month one, four in month two, then weekly or every other week. The COMP360 figures are Compass management’s own estimates. The multiplication is mine.

Take the averages, and the “slow” drug uses roughly four to six times less chair time per patient over a year.

This flips the question. For the insurer paying the bill, fewer visits is a feature. For the patient, three days a year instead of forty-odd afternoons is a feature. The only party for whom it is clearly a problem is a clinic that bills per visit.

Which means the real question about Compass is not “will the FDA say yes?”. It is “what will someone pay for one full day in that chair?”.

Compass has started to answer. Management says it will price per dose, aiming for an annual cost in the same range as Spravato, which it puts at $50,000 to $65,000 a year. The clinic’s monitoring time would be billed by the hour, under new billing codes created specifically for psychedelic sessions.

Put those two facts side by side. Similar revenue per patient per year, for roughly a fifth of the chair time.

If insurers accept that math, the long session stops being Compass’s weakness. It becomes the reason a clinic can treat far more patients with the same rooms. And there are about 8,000 interventional psychiatry clinics in the country to sell it to, by the company’s count.

That is a big if. No price is final, and management itself has cautioned that interest from insurers is not the same as coverage. But a question that large, still open a few weeks before a decision, is exactly what an opportunity looks like before it becomes obvious.

What happens next

A quick word on timing, because it is unusually tight.

A normal FDA review takes ten to twelve months. Compass holds something called a national priority voucher, which aims to cut that to one or two months. Counting from November 9, a decision could land between early December and mid-January. That is my own arithmetic, not a promise from the agency.

After an approval, the DEA is required by law to move the drug out of its current legal category within 90 days. Then come the states. About half follow the federal decision automatically, and the rest have to act on their own. Compass is aiming to launch in the first half of 2027.

I will not pretend this is low-risk. The stock fell 27.3% in a single day on November 2, to $8.41. The trigger was a trade publication reporting that Usona, a nonprofit rival, had filed its own psilocybin application, aimed at a broader group of depression patients. Neither Usona nor the FDA has confirmed it. Investors call a moment like this a binary event: one announcement, two very different outcomes.

Why this market keeps growing

So far I have talked about one company and one decision. But I did not come to this theme through a stock. I came to it through a set of numbers that I could not explain away.

Start with the United States. According to the CDC, 13.1% of Americans aged 12 and over had depression in 2021 to 2023. A decade earlier, the figure was 8.2%. That is a 60% increase in ten years.

Gallup asks the question differently and finds the same direction. In early 2026, 19.1% of American adults said they currently have or are being treated for depression, about 51 million people. Among adults under 30, the rate is 28%. In 2017, it was 13%.

Now zoom out. The World Health Organization counts more than one billion people living with a mental disorder. It estimates that depression and anxiety alone cost the world economy about $1 trillion a year in lost productivity.

THE DEMAND SIDE, IN FIVE NUMBERS
Americans 12+ with depression         13.1%, up from 8.2% a decade ago
US adults under 30 with depression    28%, up from 13% in 2017
People living with a mental disorder  more than 1 billion worldwide
Cost of depression and anxiety        about $1 trillion a year, worldwide
People who feel lonely                1 in 6 worldwide

Why is this happening? Nobody has a complete answer, and I distrust anyone who claims to. Part of the rise is simply that people are more willing to say they are struggling. But three forces keep showing up in the research.

Loneliness. The WHO estimates that one person in six worldwide is affected by it, and links it to about 871,000 deaths a year. Gallup finds that Americans who felt lonely the day before are depressed at a rate of 33%, against 13% for everyone else.

Screens. The US Surgeon General’s 2023 advisory reported that teenagers spend about three and a half hours a day on social media, and that those above three hours face double the risk of depression and anxiety symptoms. Researchers still argue about how much of this is cause and how much is correlation. The direction of the evidence is not reassuring.

Work that feels pointless. The anthropologist David Graeber made the idea famous with a book whose title I will not print in your inbox. He claimed that 20% to 50% of jobs were useless in the eyes of the people doing them. The data did not back him up: a Cambridge and Birmingham study put the share at about 5% of European workers. But the same study confirmed the part that matters here. People who feel their work is useless report clearly worse mental wellbeing.

As an investor, I do not need to settle which of these matters most. I only need to notice that none of them is going away. We are not about to become less online, less isolated, or more certain that our work matters.

Now put that next to the supply side. More than one American adult in ten already takes medication for depression, and the standard drugs work in broadly the same way they did a generation ago. The cost of that gap is enormous: one long-running study put the economic burden of major depression in the US at $326 billion a year, and found that the cost of actually treating it was only about a tenth of that. The rest is lost work, lost years and everything else.

A problem that keeps growing. Tools that have barely changed. And a bill mostly paid in lost productivity rather than in treatment.

That is the setup I saw in 2024. It is why I started looking for the companies trying something different, well before any of them had an application in front of the FDA.

What we track in Macro Notes Terminal

An edition like this one is a snapshot. It tells you what I think today. It cannot tell you what happens next week, when the FDA speaks, or the week after, when the market changes its mind.

That is why I do not stop at writing. Every thesis I publish gets its own portfolio in Macro Notes Terminal, opened on a real date and tracked in the open from that day on.

This one is called Interventional Mental Health. I opened it on September 17, 2024, long before psychedelics were back in the headlines. It is up 126.3% since.

It was built on a simple idea: in-person treatments would win, and purely digital psychiatry would not. One of its two bets has since been bought by Eli Lilly. The other is Compass, a few weeks from its FDA decision.

You can follow this portfolio live in Macro Notes Terminal, which is included for all premium subscribers. You see the positions, the performance and every new trade as it is recorded. You also see the status of the thesis itself, updated as the evidence comes in: on track, gaining traction, or under pressure.

And it is not just this one. The Terminal tracks more than 100 theses and more than 150 public portfolios, published by Macro Notes and by outside contributors. Power grids, defense, AI infrastructure, obesity drugs, space: every theme I have written about is there, with its track record, including the ones that are not working.

That is the difference between reading a thesis and following one. An edition gives you the argument. The Terminal lets you watch it being tested, in real time, long after you have closed this email.

The last big unserved market in medicine

I have spent this whole edition on a single company, and I want to be clear about why. Compass is not the thesis. Compass is the first test of it.

The thesis is that mental health is turning into a real pharmaceutical market, after decades of being treated as a dead end. The patients have always been there, by the millions, and the numbers above say there are more of them every year. What was missing was a treatment that worked differently, a way to deliver it, and someone willing to pay for it.

All three are arriving at the same time. A first psychedelic is in front of the FDA. Thousands of clinics already know how to run a monitored session. And the company that just won the obesity market has written a $2.8 billion check to get in.

When a market opens like that, the first name in the headlines is rarely the only way to invest in it, and not always the best one. There are the drug developers lined up behind Compass. There are the clinics that get paid whichever drug wins. There are the large drugmakers buying their way in. Each carries a different risk, and each deserves a different weight in a portfolio.

That is what the rest of this edition is about. Not one stock, but the whole map, and how I am investing across it.

In the premium section, you will find:

  • My complete analysis of the mental health market. Who the players are, where the money will flow, and where I think the consensus is wrong.

  • My investment playbook. How I split the theme between the drug developers, the clinics that deliver the treatments and the big buyers, and why.

  • Every position, explained. What I hold today, what each line is there to do, and why more than half the portfolio is in cash.

  • My projections. What I expect from the FDA decision and beyond, with the scenarios and the numbers behind them.

  • The next trades. What I plan to buy and sell, and the new names I intend to add to the portfolio.

Premium also gives you live access to Macro Notes Terminal, so you can follow this thesis and its portfolio in real time, well after this edition.

The FDA decision is a few weeks away. I would rather you read my plan before it lands than my explanation after.

Macro Notes Premium: The Mental Health Investment Playbook

Compass will get the headlines over the next few weeks. But a single FDA decision is a poor foundation for a portfolio, whichever way it goes.

So let me step back and show you the whole picture: how I see this market, how I have built my exposure to it, and exactly what I plan to do next.

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2026 Macro Notes · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.